Bile Duct Cancer
Advertisement
Dr. Pant describes the improved DOR and median OS seen with the treatment, and discusses the ongoing phase 3 trial.
Adding a taxane to the standard regimen of gemcitabine/cisplatin does not improve OS in patients with newly diagnosed BTC.
The GAP system was found to predict actionable genetic alterations including FGFR2 and IDH.
HERIZON-BTC-01 marks the largest phase IIb clinical trial to date for patients with previously treated HER2-positive disease.
In several different types of cancer, tumor budding is linked to poor survival outcomes.
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
While biliary tract cancer is one of the fastest-growing types of early-onset cancers, little is known about its biology.
Patients with chemotherapy-responsive disease typically undergo observation after 6 months of gemcitabine-based therapy.
Adding nanoliposomal irinotecan to fluorouracil plus leucovorin did not improve PFS or OS in cholangiocarcinoma.
Participants received pemigatinib 13.5 mg once per day for 21-day cycles with 2 weeks on and 1 week off.
The study's primary end point was overall survival.
As gem/cis is linked to low survival times, various trials have attempted to improve first-line therapy outcomes for CCA.
Drs. Ebben and Uboha break down the importance of the QUIC study, a phase 2 investigation of first-line treatment of BTC.
Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Treatment-related adverse events were mostly sitravatinib related and included hand-foot syndrome and hypertension.
A study investigated atezolizumab with varlilumab, an anti-CD27 human antibody, with or without cobimetinib, a MEK inhibitor.
Determining which patients can benefit the most from immunotherapy remains elusive.
TOPAZ-1's 3-year follow-up is the longest survival follow-up for a global, randomized phase III trial in this setting.
Dr. William Jarnagin discusses his recent study on characterizing the heterogeneity of intrahepatic cholangiocarcinoma.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.